This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tew, W. P. Articles by Ilson, D. H. Search for Related Content PubMed PubMed Citation Articles by Tew, W. P. Articles by Ilson, D. H.

Targeted Therapies for Esophageal Cancer

Memorial Sloan-Kettering Cancer Center, Department of Medicine, Gastrointestinal Oncology, New York, New York, USA

Correspondence: David H. Ilson, M.D., Ph.D., Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA. Phone: 212-639-8306; Fax: 212-717-3320; e-mail: ilsond{at}mskcc.org

Esophageal cancer is a highly aggressive neoplasm. In 2005, 14,520 Americans will be diagnosed with esophageal cancer, and more than 90% will die of their disease. On a global basis, cancer of the esophagus is the sixth leading cause of cancer death worldwide. In fact, gastric and esophageal cancers together accounted for nearly 1.3 million new cases and 980,000 deaths worldwide in 2000—more than lung, breast, or colorectal cancer. Although esophageal squamous cell carcinoma cases have steadily declined, the incidence of gastroesophageal junction adenocarcinoma has increased 4%–10% per year among U.S. men since 1976, more rapidly than for any other cancer type, and parallels rises in population trends in obesity and reflux disease.

With advances in surgical techniques and treatment, the prognosis of esophageal cancer has slowly improved over the past three decades. However, the 5-year overall survival rate (14%) remains poor, even in comparison with the dismal survival rates (4%) from the 1970s. The underlying reasons for this disappointingly low survival rate are multifold: (a) ineffective screening tools and guidelines; (b) cancer detection at an advanced stage, with over 50% of patients with unresectable disease or distant metastasis at presentation; (c) high risk for recurrent disease after esophagectomy or definitive chemoradiotherapy; (d) unreliable noninvasive tools to measure complete response to chemoradiotherapy; and (e) limited survival achieved with palliative chemotherapy alone for patients with metastatic or unresectable disease. Clearly, additional strategies are needed to detect esophageal cancer earlier and to improve our systemic treatment options. Over the past decade, the field of drug development has been transformed with the identification of and ability to direct treatment at specific molecular targets. This review focuses on novel targeted treatments in development for esophageal squamous cell carcinoma and distal esophageal and gastroesophageal junction adenocarcinoma.

Key Words. Gastroesophageal junction adenocarcinoma • Carcinoma • Esophageal squamous cancer • Targeted therapy

This article has been cited by other articles:

				L. Yu, W. K. K. Wu, Z. J. Li, Q. C. Liu, H. T. Li, Y. C. Wu, and C. H. Cho Enhancement of Doxorubicin Cytotoxicity on Human Esophageal Squamous Cell Carcinoma Cells by Indomethacin and 4-[5-(4-Chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC236) via Inhibiting P-Glycoprotein Activity Mol. Pharmacol., June 1, 2009; 75(6): 1364 - 1373. [Abstract] [Full Text] [PDF]

				S. Gillen, M. Feith, R. Gertler, R. Langer, J. Massmann, M. Sarbia, and H. Friess Testicular metastasis from adenocarcinoma of the esophagus. Ann. Thorac. Surg., March 1, 2009; 87(3): 957 - 959. [Abstract] [Full Text] [PDF]

				J Boone, F J W T. Kate, G J A Offerhaus, P J van Diest, I H M B. Rinkes, and R van Hillegersberg mTOR in squamous cell carcinoma of the oesophagus: a potential target for molecular therapy? J. Clin. Pathol., August 1, 2008; 61(8): 909 - 913. [Abstract] [Full Text] [PDF]

				J. Wang, F. Liu, H. Gao, W. Wei, X. Zhang, Y. Liang, and Y. Cheng The Symptom-to-Treatment Delay and Stage at the Time of Treatment in Cancer of Esophagus Jpn. J. Clin. Oncol., February 5, 2008; (2008) hym169v1. [Abstract] [Full Text] [PDF]

				Y. Song, C. Zhao, L. Dong, M. Fu, L. Xue, Z. Huang, T. Tong, Z. Zhou, A. Chen, Z. Yang, et al. Overexpression of cyclin B1 in human esophageal squamous cell carcinoma cells induces tumor cell invasive growth and metastasis Carcinogenesis, February 1, 2008; 29(2): 307 - 315. [Abstract] [Full Text] [PDF]

				R. C.G. Martin, Q. Liu, J. M. Wo, M. B. Ray, and Y. Li Chemoprevention of Carcinogenic Progression to Esophageal Adenocarcinoma by the Manganese Superoxide Dismutase Supplementation Clin. Cancer Res., September 1, 2007; 13(17): 5176 - 5182. [Abstract] [Full Text] [PDF]

				T. Nozoe, T. Oyama, M. Takenoyama, T. Hanagiri, K. Sugio, and K. Yasumoto Significance of Immunohistochemical Expression of Estrogen Receptors {alpha} and {beta} in Squamous Cell Carcinoma of the Esophagus Clin. Cancer Res., July 15, 2007; 13(14): 4046 - 4050. [Abstract] [Full Text] [PDF]